The CD3 epsilon subunit of the TCR complex contains two defined signaling domains, a proline-rich sequence and an ITAM. We identified a third signaling sequence in CD3 epsilon, termed the basic-rich stretch (BRS). Herein, we show that the positively charged residues of the BRS enable this region of CD3 epsilon to complex a subset of acidic phospholipids, including PI(3)P, PI(4)P, PI(5)P, PI(3,4,5)P(3), and PI(4,5)P(2). Transgenic mice containing mutations of the BRS exhibited varying developmental defects, ranging from reduced thymic cellularity to a complete block in T cell development. Peripheral T cells from BRS-modified mice also exhibited several defects, including decreased TCR surface expression, reduced TCR-mediated signaling responses to agonist peptide-loaded APCs, and delayed CD3 epsilon localization to the immunological synapse. Overall, these findings demonstrate a functional role for the CD3 epsilon lipid-binding domain in T cell biology.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954055PMC
http://dx.doi.org/10.4049/jimmunol.0900404DOI Listing

Publication Analysis

Top Keywords

cd3 epsilon
24
epsilon subunit
8
cd3
6
epsilon
6
cytoplasmic tail
4
cell
4
tail cell
4
cell receptor
4
receptor cd3
4
subunit phospholipid-binding
4

Similar Publications

Characteristics and Significance of Tertiary Lymphoid Structures Based on Molecular Subtypes in Endometrial Cancer.

Int J Gynecol Pathol

November 2024

Departments of Pathology, The Affiliated Hospital of Qingdao University, Qingdao (H.-Q.J., Y.C., Y.-H.Q., Y.-F.Y., X.-Y.Z., Y.-L.S., X.-M.X.); Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital) (S.-P.Z.), Qingdao; Department of Pathology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai (S.-Y.W.), Shandong, China.

The purpose of this study is to investigate the characteristics and significance of tertiary lymphoid structures (TLSs) in endometrial cancer (EC) based on molecular subtypes. A total of 220 patients with EC were retrospectively enrolled, including 20 with polymerase epsilon ultramutated (POLE-mut), 63 with mismatch repair deficient, 32 with p53 abnormal, and 105 with no specific molecular profile. The presence and maturity of TLSs were determined by immunohistochemical markers (CD3, CD20, CD21, and Bcl6).

View Article and Find Full Text PDF

Exploitation of CD3ζ to enhance TCR expression levels and antigen-specific T cell function.

Front Immunol

June 2024

Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, Pears Building, London, United Kingdom.

The expression levels of TCRs on the surface of human T cells define the avidity of TCR-HLA/peptide interactions. In this study, we have explored which components of the TCR-CD3 complex are involved in determining the surface expression levels of TCRs in primary human T cells. The results show that there is a surplus of endogenous TCR α/β chains that can be mobilised by providing T cells with additional CD3γ,δ,ε,ζ chains, which leads to a 5-fold increase in TCR α/β surface expression.

View Article and Find Full Text PDF

Immunosuppression is a common feature of esophageal adenocarcinoma (EAC) and has been linked to poor overall survival (OS). We hypothesized that upstream factors might negatively influence CD3 levels and T cell activity, thus promoting immunosuppression and worse survival. We used clinical data and patient samples of those who progressed from Barrett's to dysplasia to EAC, investigated gene (RNA-Seq) and protein (tissue microarray) expression, and performed cell biology studies to delineate a pathway impacting CD3 protein stability that might influence EAC outcome.

View Article and Find Full Text PDF

Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours in two open-label Phase 1 dose-escalation and -expansion studies: as a single agent with or without obinutuzumab in S1 (NCT02324257) and with atezolizumab in S2 (NCT02650713). Primary endpoints were safety, dose finding, and pharmacokinetics in S1; safety and dose finding in S2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!